Humira passes post-marketing muster in Japan psoriasis setting
This article was originally published in Scrip
Executive Summary
Abbott/Eisai's Humira (adalimumab) has cleared its conditional approval period in Japan for the additional indication of plaque psoriasis and psoriasis arthropica, clearing the way for the wider use of the product in this setting.